Last $11.50 USD
Change Today -0.10 / -0.86%
Volume 38.2K
TNXP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

tonix pharmaceuticals holdin (TNXP) Snapshot

Open
$11.67
Previous Close
$11.60
Day High
$11.67
Day Low
$11.29
52 Week High
01/13/14 - $21.00
52 Week Low
09/3/13 - $3.00
Market Cap
121.8M
Average Volume 10 Days
72.0K
EPS TTM
$-2.66
Shares Outstanding
10.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TONIX PHARMACEUTICALS HOLDIN (TNXP)

Related News

No related news articles were found.

tonix pharmaceuticals holdin (TNXP) Related Businessweek News

No Related Businessweek News Found

tonix pharmaceuticals holdin (TNXP) Details

Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence. The company was founded in 2007 and is headquartered in New York, New York.

6 Employees
Last Reported Date: 03/28/14
Founded in 2007

tonix pharmaceuticals holdin (TNXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $277.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $314.2K
Chief Scientific Officer, Secretary and Contr...
Total Annual Compensation: $238.2K
Compensation as of Fiscal Year 2013.

tonix pharmaceuticals holdin (TNXP) Key Developments

Tonix Seeks Acquisitions

Tonix Pharmaceuticals Holding Corp (NasdaqCM:TNXP) intends to make acquisitions. Tonix agreed to sell 657,000 shares of common stock in a registered direct offering at a price of $11.90 per share for aggregate gross proceeds of $7.8 million. Tonix intends to use the net proceeds of the offering to support the continued development of TNX-102 SL for the treatment of fibromyalgia, to initiate clinical trials of TNX-102 SL for the treatment of post-traumatic stress disorder, to initiate clinical trials of TNX-201 for episodic tension-type headache, further develop our other pipeline programs working capital, other general corporate purposes and possibly acquisitions of other companies products or technologies though no such acquisitions are currently contemplated.

Tonix Pharmaceuticals Holding Corp. Appoints Ronald R. Notvest as Senior Vice President of Commercial Planning and Development

Tonix Pharmaceuticals Holding Corp. has appointed Ronald R. Notvest, Ph.D. to its newly created position of Senior Vice President, Commercial Planning and Development. Dr. Notvest joins Tonix from Evidec, where he applied his expertise in the commercial assessment and analysis of drug products on behalf of a variety of biopharmaceutical industry clients.

Tonix Pharmaceuticals Holding Corp Announces Amendments to Articles of Incorporation

The Board of Directors of Tonix Pharmaceuticals Holding Corp. to amend and restate the company’s bylaws, effective on June 17, 2014. The summary of changes effected by adoption of the second amended and restated Bylaws, which summary is qualified in its entirety by reference to the Second amended and restated bylaws.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNXP:US $11.50 USD -0.10

TNXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNXP.
View Industry Companies
 

Industry Analysis

TNXP

Industry Average

Valuation TNXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TONIX PHARMACEUTICALS HOLDIN, please visit www.tonixpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.